Technology ID

Multi Protein Nanoparticle Monkeypox Vaccine

Lead Inventor
Moss, Bernard (National Institute of Allergy and Infectious Diseases (NIAID/NIH))
Development Stages
Pre-Clinical (in vitro)
Lead IC

In 2022, the World Health Organization declared an atypical outbreak of monkeypox (Mpox), which has caused approximately 30,000 cases of Mpox infection within the United States as of April 2023. Mpox represents a current threat to public health, and there is an immediate need for an effective vaccine. To address this, NIAID has developed a vaccine approach comprising virus-like nanoparticles coated with modified Mpox proteins. NIAID investigations have demonstrated that immunization has elicited a robust immune response in mice and provided protection against a lethal infection of Vaccinia virus.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

Competitive Advantages
  • A Mpox nanoparticle vaccine may have fewer side effects than available MVA based vaccines.
  • The storage and transport requirements of a Mpox nanoparticle vaccine are better suited to low resource settings than MVA vaccines.
Licensing Contact:
Hurley, Benjamin